Publications by authors named "Liyun Miao"

Background: Despite the advancements in early lung cancer detection attributed to the widespread use of low-dose computed tomography (LDCT), this technology has also led to an increasing number of pulmonary nodules (PNs) of indeterminate significance being identified. Therefore, this study was aimed to develop a model that leverages plasma methylation biomarkers and clinical characteristics to distinguish between malignant and benign PNs.

Methods: In a training cohort of 210 patients with PNs, we evaluated plasma circulating tumor DNA (ctDNA) for the presence of three lung cancer-specific methylation markers: SHOX2, SCT, and HOXA7.

View Article and Find Full Text PDF
Article Synopsis
  • FGFR is a vital receptor involved in growth and tissue repair, but its gene mutations can lead to cancer by disrupting essential processes.
  • Small molecule drugs and antibodies targeting FGFR mutations, like erdafitinib and pemigatinib, have shown clinical efficacy in treating certain cancer types.
  • Effective screening methods for FGFR variants are essential for utilizing FGFR inhibitors in treatment, and a consensus has been developed to standardize diagnosis and treatment processes.
View Article and Find Full Text PDF
Article Synopsis
  • * BRAF mutations are common in various cancers, and targeted therapies, especially BRAF inhibitors like dabrafenib and trametinib, are developed for treating solid tumors with these mutations.
  • * An expert consensus has been established to improve the diagnosis and treatment of solid tumors with BRAF mutations, focusing on summarizing their clinical features, recommending genetic testing methods, and creating a systematic approach for patient care.
View Article and Find Full Text PDF
Article Synopsis
  • Research seeks to improve chemotherapy and PD-1 inhibitors for advanced non-small-cell lung cancer (NSCLC) by analyzing circulating tumor DNA (ctDNA) from 460 patients in the CHOICE-01 study.
  • Key predictive markers such as ctDNA status, tumor mutational burden, and chromosomal instability were identified to tailor treatment strategies for better patient outcomes.
  • An integrated ctDNA-based stratification system, called blood-based genomic immune subtypes (bGIS), offers a new way to personalize therapies and monitor treatment responses in advanced NSCLC patients.
View Article and Find Full Text PDF
Article Synopsis
  • * Despite their effectiveness, there is rising concern about the incidence of interstitial lung disease or pneumonitis (ILD/p) linked to anti-HER2 ADCs, with varying mortality rates reported in studies.
  • * A panel of Chinese experts has developed guidelines for diagnosing and managing ILD/p in patients undergoing anti-HER2 ADC therapy to improve clinical practice and patient outcomes.
View Article and Find Full Text PDF

Background: Maintenance therapy could significantly improve the prognosis of patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy. Anlotinib is effective, tolerable, and convenient in administration as a third-line treatment for NSCLC. This study aimed to evaluate the efficacy and safety of maintenance therapy with anlotinib after platinum-based induction chemotherapy for patients with advanced NSCLC.

View Article and Find Full Text PDF

The capacity for embryonic cells to differentiate relies on a large-scale reprogramming of the oocyte and sperm nucleus into a transient totipotent state. In zebrafish, this reprogramming step is achieved by the pioneer factors Nanog, Pou5f3, and Sox19b (NPS). Yet, it remains unclear whether cells lacking this reprogramming step are directed towards wild type states or towards novel developmental canals in the Waddington landscape of embryonic development.

View Article and Find Full Text PDF
Article Synopsis
  • Fusion genes from the epidermal growth factor (EGF) receptor family are significant players in cancer development, especially in lung cancer, where gene fusion incidence is 0.19 to 0.27%.
  • Common partners for these fusions are CD74 and SLC3A2, and detection methods include RNA-based next-generation sequencing and pERBB3 immunohistochemistry for quick screening.
  • Currently, there are no approved specific drugs for these fusions, but treatment options like pan-ERBB inhibitors and monoclonal antibodies are being explored, with clinical trials aiming to improve outcomes for patients with solid tumors containing these gene fusions.
View Article and Find Full Text PDF

Background: Infectious etiologies of lower respiratory tract infections (LRTIs) by the conventional microbiology tests (CMTs) can be challenging. Metagenomic next-generation sequencing (mNGS) has great potential in clinical use for its comprehensiveness in identifying pathogens, particularly those difficult-to-culture organisms.

Methods: We analyzed a total of 205 clinical samples from 201 patients with suspected LRTIs using mNGS in parallel with CMTs.

View Article and Find Full Text PDF

Introduction: Treatment options for treatment-naive patients with advanced NSCLC harboring EGFR exon 20 insertion (ex20ins) mutations are limited. This study evaluated the safety, tolerability, and pharmacokinetics of YK-029A, a third-generation EGFR tyrosine kinase inhibitor, and the preliminary efficacy of YK-029A in treatment-naive patients with EGFR ex20ins mutation.

Methods: This multicenter, dose-escalation, and dose-expansion phase 1 clinical trial enrolled patients with NSCLC harboring EGFR mutations.

View Article and Find Full Text PDF

Purpose: Anlotinib is widely used in the clinical treatment of non-small cell lung cancer (NSCLC), alone or in combination with other anticancer drugs. The aim of this study was to investigate the real-world efficacy and safety of anlotinib-containing regimens.

Patients And Methods: Confirmed advanced NSCLC patients who had received anlotinib alone or in combination were enrolled.

View Article and Find Full Text PDF

The rearranged during transfection (RET) gene is one of the receptor tyrosine kinases and cell-surface molecules responsible for transmitting signals that regulate cell growth and differentiation. In non-small cell lung cancer (NSCLC), RET fusion is a rare driver gene alteration associated with a poor prognosis. Fortunately, two selective RET inhibitors (sRETi), namely pralsetinib and selpercatinib, have been approved for treating RET fusion NSCLC due to their remarkable efficacy and safety profiles.

View Article and Find Full Text PDF

Malignant pleural mesothelioma (MPM) is a malignant tumor originating from the pleura, and its incidence has been increasing in recent years. Due to the insidious onset and strong local invasiveness of MPM, most patients are diagnosed in the late stage and early screening and treatment for high-risk populations are crucial. The treatment of MPM mainly includes surgery, chemotherapy, and radiotherapy.

View Article and Find Full Text PDF

Endophytes confer fitness advantages to host plants. However, the ecological communities of endophytic fungi in the different tissues (rhizomes, stems, and leaves) of and the relationship of their endophytic fungi with polyphyllin levels remain unclear. In this study, the community diversity and differences of endophytic fungi in the rhizomes, stems, and leaves of var.

View Article and Find Full Text PDF

Nanoscale chromatin organization regulates gene expression. Although chromatin is notably reprogrammed during zygotic genome activation (ZGA), the organization of chromatin regulatory factors during this universal process remains unclear. In this work, we developed chromatin expansion microscopy (ChromExM) to visualize chromatin, transcription, and transcription factors in vivo.

View Article and Find Full Text PDF

EGFR exon 20 insertion (20ins)-positive non-small-cell lung cancer (NSCLC) is an uncommon disease with limited therapeutic options and dismal prognosis. Here we report the activity, tolerability, potential mechanisms of response and resistance for dual targeting EGFR 20ins with JMT101 (anti-EGFR monoclonal antibody) plus osimertinib from preclinical models and an open label, multi-center phase 1b trial (NCT04448379). Primary endpoint of the trial is tolerability.

View Article and Find Full Text PDF

Endophytic bacteria play crucial roles in the growth and bioactive compound synthesis of host plants. In this study, the composition and diversity of endophytic bacteria in the roots, stems, and leaves from 3-year-old artificially cultivated were investigated using Illumina HiSeq sequencing technology. Total effective reads were assigned to 936 operational taxonomic units (OTUs), belonging to 12 phyla and 289 genera.

View Article and Find Full Text PDF

Background: Camrelizumab has shown promising survival benefits in treatment-naïve advanced non-small cell lung cancer (NSCLC) patients when used in combination with chemotherapy. However, its effectiveness and safety outside the clinical trial setting are largely unknown. Therefore, we conducted NOAH-LC-101, a prospective multicenter cohort study, to investigate the real-world effectiveness and safety of camrelizumab on a large cohort of advanced NSCLC patients in daily clinical practice.

View Article and Find Full Text PDF

Thousands of long intergenic non-coding RNAs (lincRNAs) are transcribed throughout the vertebrate genome. A subset of lincRNAs enriched in developing brains have recently been found to contain cryptic open-reading frames and are speculated to encode micropeptides. However, systematic identification and functional assessment of these transcripts have been hindered by technical challenges caused by their small size.

View Article and Find Full Text PDF

Background: In the first interim analysis of the ORIENT-31 trial, compared with chemotherapy alone, sintilimab plus bevacizumab biosimilar IBI305 plus chemotherapy (pemetrexed and cisplatin) significantly improved progression-free survival in patients with EGFR-mutated non-squamous non-small-cell lung cancer (NSCLC) who progressed on EGFR tyrosine-kinase inhibitor treatment. However, the benefit of anti-PD-1 or PD-L1 antibody added to chemotherapy in this patient population remains unclear, with no prospective evidence from phase 3 trials globally. We report the results from the prespecified second interim analysis of progression-free survival between sintilimab plus chemotherapy and chemotherapy alone, the updated results of sintilimab plus IBI305 plus chemotherapy, and preliminary overall survival results.

View Article and Find Full Text PDF

Introduction: Here, we systematically assessed the safety and immunogenicity of the heterologous ChAd/BNT vaccination regimens.

Materials And Methods: We evaluated the immunogenicity by the geometric mean titers ratio (GMTR) of the neutralizing antibody and anti-spike IgG. The safety of heterologous ChAd/BNT vaccination was evaluated using the pooled risk ratios (RRs) calculated by the random-effects model about the adverse events.

View Article and Find Full Text PDF

Thymic epithelial tumors (TETs) are a relatively rare type of thoracic tumor, accounting for less than 1% of all tumors. The incidence of TETs is about 3.93/10000 in China, slightly higher than that of European and American countries.

View Article and Find Full Text PDF

Human epidermal growth factor receptor 2 (HER2) possesses tyrosine kinase activity and participates in cell growth, differentiation and migration, and survival. Its alterations, mainly including mutations, amplifications, and overexpression are associated with poor prognosis and are one of the major drivers in non-small cell lung cancer (NSCLC). Several clinical trials had been investigating on the treatments of HER2-altered NSCLC, including conventional chemotherapy, programmed death 1 (PD-1) inhibitors, tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs), however, the results were either disappointing or encouraging, but inconsistent.

View Article and Find Full Text PDF